{
    "symbol": "LYTS",
    "quarter": 1,
    "year": 2023,
    "date": "2022-11-06 12:23:02",
    "content": " I mean it's just -- it's another arrow on the quiver if you will when it's a fairly priced instrument that kind of gives you some optionality, which kind of gets to my last question which, I know you know what's common and I've asked this on conference calls before, but it really -- I just -- I look at stock price that we consider grossly undervalued with trailing 12 month revenue of $476 million on EBITDA now on a run-rate above 10%, $41 million of trailing EBITDA."
}